PCM
ARQT icon

Prelude Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Prelude Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,203
Closed -$213K – 1141
2025
Q2 		$213K Sell
15,203
-7,882
-34% -$110K 0.02% 788
2025
Q1 		$361K Buy
+23,085
New +$325K 0.03% 626
2024
Q4 		– Sell
-12,714
Closed -$118K – 1210
2024
Q3 		$118K Buy
+12,714
New +$125K 0.01% 1142
2023
Q2 		– Sell
-14,648
Closed -$161K – 1118
2023
Q1 		$161K Buy
+14,648
New +$212K 0.01% 902

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prelude Capital Management's ARQT Position: Q3 2025 in Review

Prelude Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q3 2025, closing a stake of 15,203 shares — an estimated $213K sold.

Prelude Capital Management first reported a position in ARQT in Q1 2023 and held it in 4 quarters. The position peaked at $361K in Q1 2025. 239 funds tracked by Wall St. Rank hold ARQT as of Q3 2025.

  • Prelude Capital Management reported no remaining Arcutis Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 15,203 Arcutis Biotherapeutics shares in Q3 2025, an estimated $213K.
  • Prelude Capital Management first reported a position in Arcutis Biotherapeutics in Q1 2023 and held it in 4 quarters.
  • Prelude Capital Management's Arcutis Biotherapeutics position peaked at $361K in Q1 2025.
  • 239 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.